Business
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine
About this update from Equillium, Inc.
[{"type":"text","content":"\nItolizumab continues to show clinically meaningful response in highly proteinuric subjects\n\n\nAt Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR)\n\n\nItolizumab demonstrated a favorable safety and tolerability profile\n\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study evaluating itolizumab in lupus nephritis patients was presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR). The data presented by Dr. Kenneth Kalunian, Professor, Medicine, UCSD School of Medicine, highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added to mycophenolate mofetil (MMF) and corticosteroids.\n\n\n“This data presentation represents all but the last patient in the follow up period, and a preview of what will be delivered to Ono Pharmaceutical under the terms of our strategic partnership in early 2024,” said Bruce Steel, chief executive officer at Equillium.\n\n\n“It’s important that we saw both early and large reductions in proteinuria,” said Dr. Maple Fung, chief medical officer at Equillium. “Physicians are looking for a treatment that can safely and rapidly reduce the levels of proteinuria in patients, as this is historically associated with improved long-term outcomes. These results demonstrating high complete and partial response rates compare favorably to those observed in the phase three study of voclosporin, which had an overall response rate of seventy percent at six and twelve months of active treatment. Importantly, these results occurred in the setting of patients tapering their systemic corticosteroids, maintaining stable kidney function, or eGFR, and increasing serum albumin while on study.”\n\n\nThe Type B portion of the EQUALISE study in patients with active proliferative LN (apLN) is evaluating the safety, tolerability and clinical activity of subcutaneous delivery of itolizumab. Patients must present with greater than 1 gram of proteinuria and have a recent kidney biopsy showing ISN/RPS class III or IV apLN to be eli...